Showing results (41-50 of 98) with videos related to
Sort By:
Pageof 10
Open Life Sciences|August 17, 2023
Hepatocellular carcinoma cell differentiation trajectory predicts immunotherapy, potential therapeutic drugs, and prognosis of patientsJun Qiu, Haoyun Wang, Xin Lv, et al.Biomaterials|January 3, 2026
An innate immunity-reprogramming hydrogel nips postoperative adhesions in the bud via transforming pathological healing into physiological recoveryYinqi Chen, Jiafeng Wang, Yechun Wang, et al.BMC Cancer|August 24, 2025
The immune signatures predict gastric/gastroesophageal junction cancer response to first-line anti-PD-1 blockade or chemotherapyHui Wu, Wenzhi Shu, Yongfeng Ding, et al.Journal of Controlled Release : Official Journal of the Controlled Release Society|August 4, 2018
New path to treating pancreatic cancer: TRAIL gene delivery targeting the fibroblast-enriched tumor microenvironmentHaiping Jiang, Sujuan Wang, Xuefei Zhou, et al.Translational Cancer Research|February 4, 2022
Disease progression and pseudoprogression following partial response with rare gingiva metastasis upon IBI308 (sintilimab) immunotherapy reflects the complexity of metastatic lung cancer: a case reportHaiping Jiang, Zhenguang Chen, Yuan Gao, et al.Nature Communications|April 24, 2021
Co-delivery of IOX1 and doxorubicin for antibody-independent cancer chemo-immunotherapyJing Liu, Zhihao Zhao, Nasha Qiu, et al.Biomed Research International|May 2, 2018
Mutational Profiling of Non-Small-Cell Lung Cancer Resistant to Osimertinib Using Next-Generation Sequencing in Chinese PatientsKeke Nie, Haiping Jiang, Chunling Zhang, et al.Open Medicine (Warsaw, Poland)|January 17, 2025
Predictive value of plasma sB7-H3 and YKL-40 in pediatric refractory Mycoplasma pneumoniae pneumoniaQiuMin Zhao, ShiYan Ji, HaiPing Jiang, et al.Scientific Reports|July 2, 2024
A retrospective study of adjuvant albumin-bound paclitaxel plus S-1 after D2 gastrectomy versus oxaliplatin plus S-1 in gastric cancerNing Li, Hui Wu, Xin Xu, et al.Cancer Management and Research|August 17, 2019
Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLCHelei Hou, Kang Qin, Yu Liang, et al.Pageof 10